My airport driver needs my flight number. Who needs the rest of the email?
An airport pickup shows how much personal data an AI booking service really needs, and what to ask before sharing a family itinerary.


A JOURNAL OF PERSPECTIVE
Progress gives us possibilities.
Perspective helps us choose.
Notes on health, money and the future—exploring what is changing, what we may have overlooked, and what it could mean for our lives.
TURN THE PERSPECTIVE
If we can detect more, what should we do differently?Fresh questions. Considered perspectives.
An airport pickup shows how much personal data an AI booking service really needs, and what to ask before sharing a family itinerary.
The firm is licensed. How do you check whether the person who sent the offer represents it?
What melanoma patients and investors can each learn from the same trial.
A pharmacy reading, a kaya toast excuse and one question to ask before you leave.
Three siblings split Mum’s clinic bill. What about the half-day’s pay her daughter gave up to take her?
A parent can keep the value of an investment private and still tell the family which broker to call.
Two parents can have the same EPF balance and very different room to give. What i-Legasi changes for EPF, for families and for your own retirement.
The reasoning behind Solve Everything, two real research examples, and what I take from a hopeful—but uncertain—medical future.
A fake interview was one entry point. My takeaway: security should allow for human mistakes and limit how far one breach can spread.
Humanoid robots invite us to imagine a future with more independence, better support—and perhaps someone else doing the washing-up.
Manufactured organs could expand our options. What separates a scientific breakthrough from a treatment a particular family can actually access?
Google Cloud revenue doubled, yet Alphabet shares fell. A closer look at growth, expectations and the cash needed to build AI’s future.
ER-100 brings new hope for restoring function. How should we think about longer lives when healthy years and care needs remain uncertain?
MediAsas invites a better comparison: what costs would a plan carry, what would our household retain, and could we sustain both through a difficult year?
A legacy needs a workable handover as well as valuable assets. Who could access cash, with what authority, and when?
AlphaGenome Atlas offers more promising research clues. My view on separating faster discovery from better outcomes—and asking who will be ready to benefit.
Earlier cancer detection offers a hopeful possibility: more time to understand, prepare and explore our options. What would help us make that time count?
A NOTE FROM THE EDITOR
“I’m interested in a brighter future.
And the questions that help us prepare for it.”
Hope and preparation belong in the same conversation. This journal makes room for both.
A little more about Risk Steward ↗Money & Legacy
On 19 August, Moderna shares closed 177% higher after Moderna and Merck announced that their melanoma trial had met its main goal. That means US$100 in shares at the previous close was worth about US$277 at the next one. Investors had made that move before the detailed results came out in October. What did patients actually gain?

Start with who was in the trial. These patients had already had their melanoma removed. The worry after surgery was that it might come back. Researchers tested whether adding an experimental vaccine, tailored to each patient’s tumour, to the immunotherapy drug Keytruda could help more people stay free of cancer. Both groups received Keytruda.
The headline figure was a 42% lower relative risk of recurrence or death over the follow-up period. I find the two-year results easier to picture. For every 100 patients, an estimated 82 were alive without recurrence with the combination, compared with 70 with Keytruda alone. That’s about 12 more people in every 100 reaching two years without the cancer returning. Researchers are still following patients to learn whether they live longer overall.

If a relative sent me that headline after surgery, I’d suggest they ask their specialist, “How closely does this group resemble me, and what options are open to me now?” Learning that a treatment helped people in a trial gives a family reason for hope. Knowing whether it fits their own situation gives them something they can act on.
For an investor, the starting point is different. On 6 November, Moderna raised its revenue outlook on stronger overseas demand for its COVID vaccine. Its shares closed at US$269 on 9 November and US$248.69 two days later. The cancer trial result was the same on both days. The price someone had to pay for a share had changed by more than US$20.
I can be optimistic about the medicine and still take my time over the shares. Before buying, I’d want to know what the price already assumes about approval, how many patients could receive a personalised treatment and what it would cost to make one for each of them.
Trial results · August market reaction · November closing prices · November earnings · Two-year results in plain language
A QUESTION TO CARRY FORWARD
Original article ↗